Once safety is confirmed in Phase I, the investigational product moves into Phase IIa – typically the first time it is tested in patients with the target cardiovascular condition. These studies are focused on identifying preliminary efficacy signals and dose ranges that offer optimal balance between benefit and tolerability. In cardiovascular research, this often includes measuring surrogate endpoints such as hemodynamics, biomarkers, or short-term functional changes.
We help you generate the early evidence needed to guide investment and development decisions with confidence.
We are a specialized cardiovascular CRO with a deep understanding of the regulatory, clinical, and operational landscape. Whether you’re developing a novel device, diagnostic, or drug – we bring the expertise, network, and flexibility you need at every stage of development.
How can we help you? We will get in touch shortly.
